Camp4 Therapeutics annual operating margin
2023
2024
2025
Camp4 Therapeutics Operating Margin Growth & History (CAMP)
Camp4 Therapeutics's operating margin was −1,502.43% for fiscal 2025.
View full Camp4 Therapeutics company overviewCamp4 Therapeutics annual operating margin history
| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −1,502.43% | +6639.90 pp |
| 2024 | 2024-12-31 | −8,142.33% | +6680.24 pp |
| 2023 | 2023-12-31 | −14,822.57% | — |
Camp4 Therapeutics quarterly operating margin
Q3.23
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −752.11% | +118.17 pp |
| Q1 2026 | 2026-03-31 | −1,010.12% | +516.68 pp |
| Q4 2025 | 2025-12-31 | −3,671.26% | −1518.66 pp |
| Q3 2025 | 2025-09-30 | −1,717.11% | — |
| Q2 2025 | 2025-06-30 | −870.27% | — |
| Q1 2025 | 2025-03-31 | −1,526.81% | — |
| Q4 2024 | 2024-12-31 | −2,152.61% | — |
| Q3 2023 | 2023-09-30 | −3,525.14% | — |
Camp4 Therapeutics operating margin trends
Between the periods ended 2023-12-31 and 2025-12-31, Camp4 Therapeutics's operating margin increased from −14,822.57% to −1,502.43%, a change of +13320.14 percentage points. The latest reported quarter, Q2 2026, shows −752.11%.
About the metric
What operating margin means
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
Calculation and source
How operating margin is calculated
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Camp4 Therapeutics source filings ↗Community posts
CAMP4 receives UK authorization for its first SYNGAP1 clinical study
CAMP4 Therapeutics ($CAMP) received UK authorization to include sites in its global Phase 1/2 study of CMP002, an investigational treatment for SYNGAP1-related disorder. The decision follows earlier clearances in Australia and Argentina, wh ...